Ocugen (OCGN) said Wednesday that the European Medicines Agency has granted orphan medicinal product designation for its experimental drug OCU410ST to treat ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
Orphan medicinal product designation in Europe provides benefits such as protocol assistance, reduced fees, research grants, and 10 years of market exclusivity upon approval.
The drug developer said it plans to pursue an accelerated marketing authorization application for OCU410ST.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。